Prostate Surgery News
-
TURP Primer - Transurethral resection of the prostate
The TURP Primer is especially geared towards all urologists and their assistants who are interested in learning how to perform TURP or who are already performing TURP and would like to deepen their understanding of the physical and technical fundamentals. This primer is available in German language and provides an overview of the most important TURP developments of the past 20 years to today. In ...
-
I Lost One of the Most Vital Organs - Prostate Cancer Patient Stories
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
-
Integrating Fusion Biopsies into Your Practice I
Compared to standard systematic biopsies, MRI-targeted fusion biopsies improve the detection of clinically significant prostate cancer. Studies have shown MRI can be a cost-effective and accurate first-line diagnostic tool for the early detection of prostate cancer. If the MRI is negative, patients may avoid biopsy, whereas positive results provide an action plan for biopsy and potential ...
-
First Dexter surgeries in urology carried out in Bern
Today we are announcing the successful completion of urological surgeries with Dexter® – the first and only on-demand robotic surgery platform. In a world-first, Dr. Dominik Böhlen carried out a series of urological procedures using our novel, Swiss-made surgical robot. Dr. Böhlen and his team leveraged Dexter to assist them in the most difficult work steps during various ...
-
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference in Denver, Colorado. During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory ...
By Isoray Inc.
-
Creative Medical Technology to Showcase CaverStem at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology and orthopedics, today announced that it will be exhibiting at the American Urological Association ("AUA") Annual Meeting on May 13-16, 2022 in New Orleans to showcase ...
-
Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of iaF-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced publication of key results from its Phase 3 SPOTLIGHT trial of F-rhPSMA-7.3 in recurrent prostate cancer in an abstract being presented at the ASCO 2022. Genitourinary Cancers Symposium (ASCO GU). F-rhPSMA-7.3 is an investigational ...
-
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting
BURLINGTON, Mass. and OXFORD, UK, October 19, 2021 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, III., ...
-
Profound Medical to Participate in March Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March. 42nd Annual Cowen Health Care Conference: Profound is scheduled ...
-
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners. ...
-
PROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP
REDWOOD CITY, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced positive five-year results from its 181 patient randomized WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating BPH. WATER ...
-
Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, to be held virtually ...
-
Versius launched in Poland as CMR expands presence across region
CMR Surgical – the global surgical robotics business – has today announced the introduction of the Versius® Surgical Robotic System in Poland at Salve Medica Medical Centre in Lódz, the third largest city in Poland. At Salve Medica, Versius is being used in urology, with plans to expand into general surgery and gynaecology as part of a multispecialty robotics programme. ...
-
Versius adopted for urological procedures in Pakistan
CMR Surgical – the global surgical robotics business – has today announced the successful completion of high-volume urological procedures at the Sindh Institute of Urology and Transplantation (SIUT) using the next generation surgical robotic system, Versius®, in Pakistan. SIUT is a renowned, charitable institute, providing free state of the art medical treatment to all patients, ...
-
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. CAPTAIN (A Comparison of TULSA Procedure vs. Radical ...
-
« Back Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems
First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates REDWOOD CITY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it now has five ...
-
Versius adopted by Guy’s and St Thomas’ NHS Foundation Trust to improve access to robotic surgery in London
CMR Surgical (CMR) – a global surgical robotics business – today announced Guy’s and St Thomas’ NHS Foundation Trust as the latest NHS Trust, and first site in London, to adopt the Versius robot. The renowned teaching hospital has adopted the versatile technology in order to increase patient access to minimal access (or keyhole) surgery across both of its London sites. ...
-
Lightpoint Medical to Present Positive Clinical Trial Data for SENSEI Miniature Gamma Probe in Prostate Cancer Surgery
Lightpoint Medical, a leading medical device company developing and marketing innovative technologies for intra-operative cancer detection, announced clinical trial results today to support the use of the company's miniature surgical gamma probe, SENSEI®, in prostate sentinel lymph node detection. The interim results from the multi-center clinical trial, which involves cancer centers at ...
-
Beyond Death Valley: Medtech Veteran Breathes New Life into HIFU Company
Ryan Rhodes, new CEO of EDAP USA was featured in MDDI this week. Rhodes hales from Intuitive Surgical where he helped build the DaVinci Robot brand. He compares HIFU to the early days of robotic surgery: “The HIFU market is still in its infancy, and Rhodes said it reminds him of his early days at Intuitive Surgical, when the Irvine, CA-based robotics company was focused on prostate cancer, ...
By EDAP TMS
-
Data presented at the American Urology Association annual conference
Data includes preliminary results from 39 patients at 4 centers across 3 countries – the temporary implant demonstrated the procedure was safe and provided immediate and sustained symptom relief. Prodeon Medical, Inc., a medical device company developing a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) caused by enlarged and obstructive benign prostatic ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you